Macy’s Q2 Sales Beat Estimates, Q3 Guidance Lags

Macy’s reported second-quarter comparable sales growth of 2.7%, outpacing market expectations by 2.0 percentage points. The result was driven by an 11.3% lift at Bloomingdale’s, 6.2% at Bluemercury, and 1.1% at core Macy’s stores. Adjusted earnings per share reached $0.40, up from $0.35 in the prior year, aided by sales momentum and operating cost leverage.

The retailer marked its fifth consecutive quarter of comparable sales gains, ending a two-year decline. Average unit retail prices rose 9%, a sign of progress in its premiumization strategy. According to GN markets/earnings (en-US), the company’s strategic plan to upgrade namesake stores and increase luxury sales is beginning to show measurable results in both revenue and cost efficiency.

Guidance Falls Short of Forecasts

Macy’s guided for third-quarter adjusted EBITDA margin between 3.5% and 4.0% and adjusted loss per share of $0.19 to $0.23. These figures came in below analyst estimates, triggering a roughly 3% share price drop in early trading on Sept. 10. The weak Q3 outlook reflects heightened spending on promotions and discounts to defend market share amid soft economic conditions and rising gas and transportation costs.

Margin Gains Face Structural Limits

Macy’s projects long-run annual same-store sales growth of 0.5% and an operating margin of 4.5%, up from roughly 4.0% recently. While store closures and operational efficiencies should support margin improvement, the company’s lack of an economic moat constrains its ability to sustainably lift profitability without stronger top-line growth. The strategy of increased promotional spending, while reasonable for share defense, underscores the limits of its competitive position in driving margin expansion.

2026 Outlook Aligns With Estimates

For fiscal 2026, Macy’s expects comparable sales growth of 1% to 1.5% and adjusted EPS between $2.15 and $2.35, in line with market expectations. The company’s fair value estimate stands at $25.50, with no anticipated material change. Investors appear to be underweighting the progress Macy’s has made in stabilizing sales and improving balance-sheet health, even as near-term margin headwinds persist.